Literature DB >> 33987257

Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson's disease.

Na Zhang1,2, Chuanxi Tang1, Qiong Ma3, Wei Wang1,4, Mingyu Shi1,5, Xiaoyu Zhou1,5, Fangfang Chen6, Chengcheng Ma1, Xue Li3, Gang Chen1,5, Dianshuai Gao1.   

Abstract

BACKGROUND: Given the increased incidence of Parkinson's disease (PD) and the lack of accurate early diagnosis of PD with cognitive impairment (PD-CI), we compared the serum metabolomes and proteomes of 26 patients with PD without cognitive impairment (PD-N) and 31 patients with PD-CI by combining grade-dependent proteomics and metabolomics analyses.
METHODS: Logistic and linear regression analyses were performed for differential metabolic indicators, cognition, and clinical diagnosis. Ingenuity pathway analysis (IPA) was used to identify metabolites linked to different pathways. Bioinformatics revealed 16 differentially expressed proteins and 32 metabolites.
RESULTS: The positive metabolic indicators related to the differential proteins were one sphingolipid, five phosphatidylcholines, and five long-chain fatty acids. The obtained metabolic and proteomics IPA network highlighted the central term of this network was inflammation and abnormal lipid metabolism which are prominent in PD-CI. There was a strong negative correlation between the Mini-Mental State Examination (MMSE)score and LPC (18:1). The receiver operating characteristic (ROC) of LPC (18:1) for PD-N and PD-CI showed that the area under the curve (AUC) value was 0.660 (P=0.039).
CONCLUSIONS: In conclusion, serum LPC (18:1) is inversely linked to cognition in PD and presented its potential clinical value in distinguishing the presence or absence of cognitive impairment in PD. The deeper implication of our discovery indicates abnormal lipid metabolism is associated with changes of cognitive status and suggests the potential for possibility of immune system- inflammatory involvement. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Parkinson’s disease (PD); cognitive function; long chain fatty acid metabolism; metabolomics; proteomics

Year:  2021        PMID: 33987257      PMCID: PMC8105844          DOI: 10.21037/atm-20-4583

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  39 in total

Review 1.  Cerebral metabolic adaptation and ketone metabolism after brain injury.

Authors:  Mayumi L Prins
Journal:  J Cereb Blood Flow Metab       Date:  2007-08-08       Impact factor: 6.200

Review 2.  Lipid Biomarkers in Alzheimer's Disease.

Authors:  Amira Zarrouk; Meryam Debbabi; Maryem Bezine; El Mostafa Karym; Asmaa Badreddine; Olivier Rouaud; Thibault Moreau; Mustapha Cherkaoui-Malki; Mohamed El Ayeb; Boubker Nasser; Mohamed Hammami; Gerard Lizard
Journal:  Curr Alzheimer Res       Date:  2018-02-22       Impact factor: 3.498

3.  Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.

Authors:  Jean-Pierre Trezzi; Sara Galozzi; Christian Jaeger; Katalin Barkovits; Kathrin Brockmann; Walter Maetzler; Daniela Berg; Katrin Marcus; Fay Betsou; Karsten Hiller; Brit Mollenhauer
Journal:  Mov Disord       Date:  2017-08-26       Impact factor: 10.338

Review 4.  Parkinson disease.

Authors:  Werner Poewe; Klaus Seppi; Caroline M Tanner; Glenda M Halliday; Patrik Brundin; Jens Volkmann; Anette-Eleonore Schrag; Anthony E Lang
Journal:  Nat Rev Dis Primers       Date:  2017-03-23       Impact factor: 52.329

Review 5.  Sphingosine 1-phosphate: a prototype of a new class of second messengers.

Authors:  S Spiegel
Journal:  J Leukoc Biol       Date:  1999-03       Impact factor: 4.962

Review 6.  Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders.

Authors:  Akhlaq A Farooqui
Journal:  Neuroscientist       Date:  2009-08       Impact factor: 7.519

7.  CSF Aβ42 predicts early-onset dementia in Parkinson disease.

Authors:  Guido Alves; Johannes Lange; Kaj Blennow; Henrik Zetterberg; Ulf Andreasson; Marthe G Førland; Ole-Bjørn Tysnes; Jan P Larsen; Kenn F Pedersen
Journal:  Neurology       Date:  2014-04-18       Impact factor: 9.910

8.  A clinicopathologic study of 100 cases of Parkinson's disease.

Authors:  A J Hughes; S E Daniel; S Blankson; A J Lees
Journal:  Arch Neurol       Date:  1993-02

9.  Lysophosphatidylcholine induces glial cell activation: role of rho kinase.

Authors:  Abdullah Md Sheikh; Atsushi Nagai; Jae K Ryu; James G McLarnon; Seung U Kim; Junichi Masuda
Journal:  Glia       Date:  2009-06       Impact factor: 7.452

10.  S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms.

Authors:  B G Crowell; R Benson; D Shockley; C G Charlton
Journal:  Behav Neural Biol       Date:  1993-05
View more
  2 in total

1.  Serum Metabonomics Reveals Key Metabolites in Different Types of Childhood Short Stature.

Authors:  Guoyou Chen; Jinming Wang; Yisi Jing; Chunxiang Li; Wenyue Zhang; Shuang Yang; Ye Song; Xin Wang; Jincheng Liu; Dejun Yu; Zhichun Xu
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

2.  Serum metabolomic characterization of PLA2G6-associated dystonia-parkinsonism: A case-control biomarker study.

Authors:  Chen Chen; Min-Min Lou; Yi-Min Sun; Fang Luo; Feng-Tao Liu; Su-Shan Luo; Wen-Yuan Wang; Jian Wang
Journal:  Front Neurosci       Date:  2022-08-11       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.